

SECOND REGULAR SESSION

# SENATE BILL NO. 1605

## 103RD GENERAL ASSEMBLY

---

INTRODUCED BY SENATOR HENDERSON.

6874S.01I

KRISTINA MARTIN, Secretary

### AN ACT

To repeal section 195.017, RSMo, and to enact in lieu thereof one new section relating to 7-hydroxymitragynine.

---

*Be it enacted by the General Assembly of the State of Missouri, as follows:*

Section A. Section 195.017, RSMo, is repealed and one new section enacted in lieu thereof, to be known as section 195.017, to read as follows:

195.017. 1. The department of health and senior services shall place a substance in Schedule I if it finds that the substance:

- 4 (1) Has high potential for abuse; and
- 5 (2) Has no accepted medical use in treatment in the
- 6 United States or lacks accepted safety for use in treatment
- 7 under medical supervision.

8 2. Schedule I:

- 9 (1) The controlled substances listed in this subsection are included in Schedule I;
- 10 (2) Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers and salts is possible within the specific chemical designation:
- 11 (a) Acetyl-alpha-methylfentanyl (N-(1-(1-methyl-2-phenethyl)-4-piperidinyl)-N-phenylacetamide);

18 (b) Acetylmethadol;  
19 (c) Acetyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-  
20 phenylacetamide);  
21 (d) Acryl fentanyl (- (1-phenethylpiperidin-4-yl)-N-  
22 phenylacrylamide);  
23 (e) AH-7921 (3,4-dichloro-N-[(1-dimethylamino)  
24 cyclohexylmethyl] benzamide);  
25 (f) Allylprodine;  
26 (g) Alphacetylmethadol (except levoalphacetylmethadol,  
27 also known as levo-alpha-acetylmethadol levothadyl acetate  
28 or LAAM);  
29 (h) Alphameprodine;  
30 (i) Alphamethadol;  
31 (j) Alpha-methylfentanyl (N-1-(alphamethyl-beta-  
32 phenyl) ethyl-4-piperidyl) propionanilide; 1-(1-methyl-2-  
33 phenylethyl)-4 ((N-propanilido) piperidine);  
34 (k) Alpha-methylthiofentanyl (N-(1-methyl-2-(2-  
35 thienyl) ethyl-4-piperidinyl)-N-phenylpropanamide);  
36 (l) Benzethidine;  
37 (m) Betacetylmethadol;  
38 (n) Beta-hydroxyfentanyl (N-(1-(2-hydroxy-2-phenethyl)-  
39 4-piperidinyl)-N-phenylpropanamide);  
40 (o) Beta-hydroxy-3-methylfentanyl (N-(1-(2-hydroxy-2-  
41 phenethyl)-3-methyl-4-piperidinyl)-N-phenylpropanamide);  
42 (p) Betameprodine;  
43 (q) Betamethadol;  
44 (r) Betaprodine;  
45 (s) Clonitazene;  
46 (t) Dextromoramide;  
47 (u) Diampromide;  
48 (v) Cyclopropyl fentanyl;  
49 (w) Diethylthiambutene;

50 (x) Difenoxin;  
51 (y) Dimenoxadol;  
52 (z) Dimepheptanol;  
53 (aa) Dimethylthiambutene;  
54 (bb) Dioxaphetyl butyrate;  
55 (cc) Dipipanone;  
56 (dd) Ethylmethylthiambutene;  
57 (ee) Etonitazene;  
58 (ff) Etoxeridine;  
59 (gg) 4-fluoroisobutyryl fentanyl -(4-fluorophenyl)-N-  
60 (1-phenethylpiperidin-4-yl)isobutyramide;  
61 (hh) Furanyl fentanyl -(1-phenethylpiperidin-4-yl)-N-  
62 phenylfuran-2-carboxamide;  
63 (ii) Furethidine;  
64 (jj) Hydroxypethidine;  
65 (kk) Ketobemidone;  
66 (ll) Levomoramide;  
67 (mm) Levophenacylmorphan;  
68 (nn) 3-Methylfentanyl (N-(3-methyl-1-(2-phenylethyl)-4-  
69 piperidyl)-N-phenylpropanamide), its optical and geometric  
70 isomers, salts, and salts of isomers;  
71 (oo) 3-Methylthiofentanyl (N-((3-methyl-1-(2-  
72 thienyl)ethyl-4-piperidinyl)-N-phenylpropanamide);  
73 (pp) Methoxyacetyl fentanyl (2-methoxy-N-(1-  
74 phenethylpiperidin-4-yl)-N-phenylacetamide);  
75 (qq) Morpheridine;  
76 (rr) MPPP (1-methyl-4-phenyl-4-propionoxypiperidine);  
77 (ss) MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)  
78 piperazine);  
79 (tt) Noracymethadol;  
80 (uu) Norlevorphanol;  
81 (vv) Normethadone;

82 (ww) Norpipanone;  
83 (xx) Ocfentanil N-(2-fluorophenyl)-2-methoxy-N-(1-  
84 phenethylpiperidin-4-yl)acetamide;  
85 (yy) Ortho-fluorofentanyl (N-2-(1-phenethylpiperidin-  
86 yl)propionamide); other name 2-fluorofentanyl;  
87 (zz) para-fluorobutyryl fentanyl (N-4-fluorophenyl)-N-  
88 (1-phenethylpiperidin-4-yl)butyramide;  
89 (aaa) Para-fluorofentanyl (N-(4-fluorophenyl)-N-(1-(2-  
90 phenethyl)-4-piperidinyl) propanamide;  
91 (bbb) PEPAP (1-(2-phenethyl)-4-phenyl-4-  
92 acetoxy piperidine);  
93 (ccc) Phenadoxone;  
94 (ddd) Phenampronide;  
95 (eee) Phenomorphan;  
96 (fff) Phenoperidine;  
97 (ggg) Piritramide;  
98 (hhh) Proheptazine;  
99 (iii) Properidine;  
100 (jjj) Propiram;  
101 (kkk) Racemoramide;  
102 (lll) Tetrahydrofuryl fentanyl (N-(1-  
103 phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-  
104 carboxamide);  
105 (mmm) Thiofentanyl (-phenyl-N-(1-(2-thienyl)ethyl-4-  
106 piperidinyl)propanamide;  
107 (nnn) Tilidine;  
108 (ooo) Trimeperidine;  
109 (3) Any of the following opium derivatives, their  
110 salts, isomers and salts of isomers unless specifically  
111 excepted, whenever the existence of these salts, isomers and  
112 salts of isomers is possible within the specific chemical  
113 designation:

114 (a) Acetorphine;  
115 (b) Acetyldihydrocodeine;  
116 (c) Benzylmorphine;  
117 (d) Codeine methylbromide;  
118 (e) Codeine-N-Oxide;  
119 (f) Cyprenorphine;  
120 (g) Desomorphine;  
121 (h) Dihydromorphine;  
122 (i) Drotebanol;  
123 (j) Etorphine (except hydrochloride salt);  
124 (k) Heroin;  
125 (l) Hydromorphenol;  
126 (m) Methyldesorphine;  
127 (n) Methyldihydromorphine;  
128 (o) Morphine methylbromide;  
129 (p) Morphine methylsulfonate;  
130 (q) Morphine-N-Oxide;  
131 (r) Myrophine;  
132 (s) Nicocodeine;  
133 (t) Nicomorphine;  
134 (u) Normorphine;  
135 (v) Pholcodine;  
136 (w) Thebacon;  
137 (4) Any of the following opiate similar synthetic  
138 substances scheduled by the U.S. Drug Enforcement  
139 Administration as substances that share a pharmacological  
140 profile similar to fentanyl, morphine, and other synthetic  
141 opioids, unless specifically excepted or unless listed in  
142 another schedule:  
143 (a) Butyryl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-  
144 phenylbutyramide);

145 (b) U-47700 (3,4-Dichloro-N-[2-(dimethylamino)  
146 cyclohexyl]--methyl benzamide).

147 (5) Any material, compound, mixture or preparation  
148 which contains any quantity of the following hallucinogenic  
149 substances, their salts, isomers and salts of isomers,  
150 unless specifically excepted, whenever the existence of  
151 these salts, isomers, and salts of isomers is possible  
152 within the specific chemical designation:

- 153 (a) Alpha-ethyltryptamine;
- 154 (b) 4-bromo-2,5-dimethoxyamphetamine;
- 155 (c) 4-bromo-2,5-dimethoxyphenethylamine;
- 156 (d) 2,5-dimethoxyamphetamine;
- 157 (e) 2,5-dimethoxy-4-ethylamphetamine;
- 158 (f) 2,5-dimethoxy-4-(n)-propylthiophenethylamine;
- 159 (g) 2-(2,5-Dimethoxy-4-(n)-propylphenyl) ethanamine;
- 160 (h) 2-(2,5-Dimethoxy-4-ethylphenyl) ethanamine;
- 161 (i) 2-(2,5-Dimethoxy-4-methylphenyl) ethanamine;
- 162 (j) 2-(2,5-Dimethoxy-4-nitro-phenyl) ethanamine;
- 163 (k) 2-(2,5-Dimethoxyphenyl) ethanamine;
- 164 (l) 2-(4-Chloro-2,5-dimethoxyphenyl) ethanamine;
- 165 (m) 2-(4-Ethylthio-2,5-dimethoxyphenyl) ethanamine;
- 166 (n) 2-(4-Iodo-2,5-dimethoxyphenyl) ethanamine;
- 167 (o) 2-(4-Isopropylthio)-2,5-dimethoxyphenyl)  
168 ethanamine;
- 169 (p) 4-methoxyamphetamine;
- 170 (q) 5-methoxy-3,4-methylenedioxymphetamine;
- 171 (r) 4-methyl-2, 5-dimethoxyamphetamine;
- 172 (s) 3,4-methylenedioxymphetamine;
- 173 (t) 3,4-methylenedioxymethamphetamine;
- 174 (u) 3,4-methylenedioxy-N-ethylamphetamine;
- 175 (v) N-hydroxy-3, 4-methylenedioxymphetamine;
- 176 (w) 3,4,5-trimethoxyamphetamine;

177 (x) 5-MeO-DMT or 5-methoxy-N,N-dimethyltryptamine;

178 (y) Alpha-methyltryptamine;

179 (z) Bufotenine;

180 (aa) Diethyltryptamine;

181 (bb) Dimethyltryptamine;

182 (cc) 5-methoxy-N,N-diisopropyltryptamine;

183 (dd) Ibogaine;

184 (ee) Lysergic acid diethylamide;

185 (ff) Marijuana or marihuana, except industrial hemp;

186 (gg) Mescaline;

187 (hh) Parahexyl;

188 (ii) Peyote, to include all parts of the plant

189 presently classified botanically as *Lophophora williamsii*

190 Lemaire, whether growing or not; the seeds thereof; any

191 extract from any part of such plant; and every compound,

192 manufacture, salt, derivative, mixture or preparation of the

193 plant, its seed or extracts;

194 (jj) N-ethyl-3-piperidyl benzilate;

195 (kk) N-methyl-3-piperidyl benzilate;

196 (ll) Psilocybin;

197 (mm) Psilocyn;

198 (nn) Tetrahydrocannabinols naturally contained in a

199 plant of the genus *Cannabis* (cannabis plant), except

200 industrial hemp, as well as synthetic equivalents of the

201 substances contained in the cannabis plant, or in the

202 resinous extractives of such plant, or synthetic substances,

203 derivatives and their isomers, or both, with similar

204 chemical structure and pharmacological activity to those

205 substances contained in the plant, such as the following:

206 a. 1 cis or trans tetrahydrocannabinol and their

207 optical isomers;

208       b. 6 cis or trans tetrahydrocannabinol and their  
209       optical isomers;

210       c. 3,4 cis or trans tetrahydrocannabinol and their  
211       optical isomers;

212       d. Any compounds of these structures, regardless of  
213       numerical designation of atomic positions covered;

214        (oo) Ethylamine analog of phencyclidine;

215        (pp) Pyrrolidine analog of phencyclidine;

216        (qq) Thiophene analog of phencyclidine;

217        (rr) 1-[1-(2-thienyl)cyclohexyl]pyrrolidine;

218        (ss) *Salvia divinorum*;

219        (tt) *Salvinorin A*;

220        (uu) Synthetic cannabinoids:

221        a. Any compound structurally derived from 3-(1-  
222        naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane by  
223        substitution at the nitrogen atom of the indole ring by  
224        alkyl, haloalkyl, alkenyl, cycloalkylmethyl,  
225        cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-  
226        morpholinyl)ethyl group, whether or not further substituted  
227        in the indole ring to any extent, whether or not substituted  
228        in the naphthyl ring to any extent. Including, but not  
229        limited to:

230        (i) AM2201, or 1-(5-fluoropentyl)-3-(1-  
231        naphthoyl)indole;

232        (ii) JWH-007, or 1-pentyl-2-methyl-3-(1-  
233        naphthoyl)indole;

234        (iii) JWH-015, or 1-propyl-2-methyl-3-(1-  
235        naphthoyl)indole;

236        (iv) JWH-018, or 1-pentyl-3-(1-naphthoyl)indole;

237        (v) JWH-019, or 1-hexyl-3-(1-naphthoyl)indole;

238        (vi) JWH-073, or 1-butyl-3-(1-naphthoyl)indole;

239 (vii) JWH-081, or 1-pentyl-3-(4-methoxy-1-  
240 naphthoyl)indole;  
241 (viii) JWH-098, or 1-pentyl-2-methyl-3-(4-methoxy-1-  
242 naphthoyl)indole;  
243 (ix) JWH-122, or 1-pentyl-3-(4-methyl-1-  
244 naphthoyl)indole;  
245 (x) JWH-164, or 1-pentyl-3-(7-methoxy-1-  
246 naphthoyl)indole;  
247 (xi) JWH-200, or 1-(2-(4-(morpholinyl)ethyl))-3-(1-  
248 naphthoyl)indole;  
249 (xii) JWH-210, or 1-pentyl-3-(4-ethyl-1-  
250 naphthoyl)indole;  
251 (xiii) JWH-398, or 1-pentyl-3-(4-chloro-1-  
252 naphthoyl)indole;  
253 b. Any compound structurally derived from 3-(1-  
254 naphthoyl)pyrrole by substitution at the nitrogen atom of  
255 the pyrrole ring by alkyl, haloalkyl, alkenyl,  
256 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-  
257 piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether  
258 or not further substituted in the pyrrole ring to any  
259 extent, whether or not substituted in the naphthyl ring to  
260 any extent;  
261 c. Any compound structurally derived from 1-(1-  
262 naphthylmethyl)indene by substitution at the 3-position of  
263 the indene ring by alkyl, haloalkyl, alkenyl,  
264 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-  
265 piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether  
266 or not further substituted in the indene ring to any extent,  
267 whether or not substituted in the naphthyl ring to any  
268 extent;  
269 d. Any compound structurally derived from 3-  
270 phenylacetylindole by substitution at the nitrogen atom of

271 the indole ring with alkyl, haloalkyl, alkenyl,  
272 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-  
273 piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether  
274 or not further substituted in the indole ring to any extent,  
275 whether or not substituted in the phenyl ring to any  
276 extent. Including, but not limited to:

277 (i) JWH-201, or 1-pentyl-3-(4-  
278 methoxyphenylacetyl)indole;

279 (ii) JWH-203, or 1-pentyl-3-(2-  
280 chlorophenylacetyl)indole;

281 (iii) JWH-250, or 1-pentyl-3-(2-  
282 methoxyphenylacetyl)indole;

283 (iv) JWH-251, or 1-pentyl-3-(2-  
284 methylphenylacetyl)indole;

285 (v) RCS-8, or 1-(2-cyclohexylethyl)-3-(2-  
286 methoxyphenylacetyl)indole;

287 e. Any compound structurally derived from 2-(3-  
288 hydroxycyclohexyl)phenol by substitution at the 5-position  
289 of the phenolic ring by alkyl, haloalkyl, alkenyl,  
290 cycloalkylmethyl, cycloalkylethyl, 1-(N-methyl-2-  
291 piperidinyl)methyl or 2-(4-morpholinyl)ethyl group, whether  
292 or not substituted in the cyclohexyl ring to any extent.

293 Including, but not limited to CP 47, 497 and homologues, or  
294 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methyloctan-2-  
295 yl)phenol, where side chain n=5, and homologues where side  
296 chain n=4, 6, or 7;

297 f. Any compound containing a 3-(benzoyl)indole  
298 structure with substitution at the nitrogen atom of the  
299 indole ring by alkyl, haloalkyl, alkenyl, cycloalkylmethyl,  
300 cycloalkylethyl, 1-(N-methyl-2-piperidinyl)methyl or 2-(4-  
301 morpholinyl)ethyl group, whether or not further substituted  
302 in the indole ring to any extent and whether or not

303 substituted in the phenyl ring to any extent. Including,  
304 but not limited to:

305 (i) AM-694, or 1-(5-fluoropentyl)-3-(2-  
306 iodobenzoyl)indole;  
307 (ii) RCS-4, or 1-pentyl-3-(4-methoxybenzoyl)indole (SR-  
308 19 and RCS-4);

309 g. CP 50,556-1, or [(6S,6aR,9R,10aR)-9-hydroxy-6-  
310 methyl-3-[(2R)-5-phenylpentan-2-yl] oxy-5,6,6a,7,8,9,10,10a-  
311 octahydrophenanthridin-1-yl] acetate;

312 h. HU-210, or (6aR,10aR)-9-(hydroxymethyl)-6,6-  
313 dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-  
314 tetrahydrobenzo[c]chromen-1-ol;

315 i. HU-211, or Dexanabinol, (6aS,10aS)-9-(hydroxymethyl)-  
316 6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-  
317 tetrahydrobenzo[c]chromen-1-ol;

318 j. Dimethylheptylpyran, or DMHP;

319 (6) Any material, compound, mixture or preparation  
320 containing any quantity of the following substances having a  
321 depressant effect on the central nervous system, including  
322 their salts, isomers and salts of isomers whenever the  
323 existence of these salts, isomers and salts of isomers is  
324 possible within the specific chemical designation:

325 (a) Gamma-hydroxybutyric acid;

326 (b) Mecloqualone;

327 (c) Methaqualone;

328 (7) Any material, compound, mixture or preparation  
329 containing any quantity of the following substances having a  
330 stimulant effect on the central nervous system, including  
331 their salts, isomers and salts of isomers:

332 (a) Aminorex;

333 (b) N-benzylpiperazine;

334 (c) Cathinone;

335 (d) Fenethylline;

336 (e) 3-Fluoromethcathinone;

337 (f) 4-Fluoromethcathinone;

338 (g) Mephedrone, or 4-methylmethcathinone;

339 (h) Methcathinone;

340 (i) 4-methoxymethcathinone;

341 (j) (+, -) cis-4-methylaminorex ((+,-) cis-4,5-dihydro-4-

342 methyl-5-phenyl-2-oxazolamine);

343 (k) Methylenedioxypyrovalerone, MDPV, or 1-(1,3-

344 Benzodioxol-5-yl)-2-(1-pyrrolidinyl)-1-pentanone;

345 (l) Methylone, or 3,4-Methylenedioxymethcathinone;

346 (m) 4-Methyl-alpha-pyrrolidinobutiotiophenone, or MPBP;

347 (n) N-ethylamphetamine;

348 (o) N,N-dimethylamphetamine;

349 (p) Quinolin-8-yl 1-pentyl-1H-indole-3-carboxylate (PB-

350 22; QUPIC);

351 (q) Quinolin-8-yl 1-(5-fluoropentyl)-1H-indole-3-

352 carboxylate (5-fluoro-PB-22; 5F-PB-22);

353 (r) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-

354 fluorobenzyl)-1H-indazole-3-carboxamide (AB-FUBINACA);

355 (s) N-(1-amino-3, 3-dimethyl-1-oxobutan-2-yl)-1-pentyl-

356 1H-indazole-3-carboxamide (ADB-PINACA);

357 (8) A temporary listing of substances subject to

358 emergency scheduling under federal law shall include any

359 material, compound, mixture or preparation which contains

360 any quantity of the following substances:

361 (a) (1-pentyl-1H-indol-3-yl)(2,2,3,3-

362 tetramethylcyclopropyl)methanone, its optical, positional,

363 and geometric isomers, salts, and salts of isomers;

364 (b) [1-(5-fluoro-pentyl)-1H-indol-3-yl](2,2,3,3-

365 tetramethylcyclopropyl)methanone, its optical, positional,

366 and geometric isomers, salts, and salts of isomers;

367 (c) N-(1-adamantyl)-1-pentyl-1H-indazole-3-  
368 carboxamide, its optical, positional, and geometric isomers,  
369 salts, and salts of isomers;

370 (d) 2-(4-iodo-2,5-dimethoxyphenyl)-N-(2-  
371 methoxybenzyl)ethanamine, its optical, positional, and  
372 geometric isomers, salts, and salts of isomers;

373 (e) 2-(4-chloro-2,5-dimethoxyphenyl)-N-(2-  
374 methoxybenzyl)ethanamine, its optical, positional, and  
375 geometric isomers, salts, and salts of isomers;

376 (f) 2-(4-bromo-2,5-dimethoxyphenyl)-N-(2-  
377 methoxybenzyl)ethanamine, its optical, positional, and  
378 geometric isomers, salts, and salts of isomers;

379 (g) 4-methyl-N-ethylcathinone, its optical,  
380 positional, and geometric isomers, salts, and salts of  
381 isomers;

382 (h) 4-methyl-alpha-pyrrolidinopropiophenone, its  
383 optical, positional, and geometric isomers, salts, and salts  
384 of isomers;

385 (i) Alpha-pyrrolidinopentiophenone, its optical,  
386 positional, and geometric isomers, salts, and salts of  
387 isomers;

388 (j) Butylone, its optical, positional, and geometric  
389 isomers, salts, and salts of isomers;

390 (k) Pentedrone, its optical, positional, and geometric  
391 isomers, salts, and salts of isomers;

392 (l) Pentyrone, its optical, positional, and geometric  
393 isomers, salts, and salts of isomers;

394 (m) Naphyrone, its optical, positional, and geometric  
395 isomers, salts, and salts of isomers;

396 (n) Alpha-pyrrolidinobutiophenone, its optical,  
397 positional, and geometric isomers, salts, and salts of  
398 isomers;

399 (o) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-  
400 (cyclohexylmethyl)-1H-indazole-3-carboxamide, its optical,  
401 positional, and geometric isomers, salts, and salts of  
402 isomers;

403 (p) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentyl-1H-  
404 indazole-3-carboxamide, its optical, positional, and  
405 geometric isomers, salts, and salts of isomers;

406 (q) [1-(5-fluoropentyl)-1H-indazole-3-yl] (naphthalen-1-  
407 yl)methanone, its optical, positional, and geometric  
408 isomers, salts, and salts of isomers;

409 (r) N-[1-[2-hydroxy-2-(thiophen-2-yl) ethyl]piperidin-  
410 4-yl]-N-phenylpropionamide, its isomers, esters, ethers,  
411 salts, and salts of isomers, esters, and ethers;

412 (s) N-(1-phenethylpiperidin-4-yl)-N-phenylacetamide,  
413 its optical, positional, and geometric isomers, salts, and  
414 salts of isomers;

415 (t) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-  
416 (cyclohexylmethyl)-1H-indazole-3-carboxamide, its optical,  
417 positional, and geometric isomers, salts, and salts of  
418 isomers;

419 (u) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-  
420 carboxamido)-3,3-dimethylbutanoate, its optical, positional,  
421 and geometric isomers, salts, and salts of isomers;

422 (v) methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-  
423 carboxamido)-3-methylbutanoate, its optical, positional, and  
424 geometric isomers, salts, and salts of isomers;

425 (w) N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-  
426 3-carboxamide, its optical, positional, and geometric  
427 isomers, salts, and salts of isomers;

428 (x) N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(4-  
429 fluorobenzyl)-1H-indazole-3-carboxamide, its optical,

430 positional, and geometric isomers, salts, and salts of  
431 isomers;

432 (y) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-  
433 carboxamido)-3,3-dimethylbutanoate, its optical, positional,  
434 and geometric isomers, salts, and salts of isomers;

435 (z) methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-  
436 carboxamido)-3,3-dimethylbutanoate, its optical, positional,  
437 and geometric isomers, salts, and salts of isomers;

438 (aa) N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-  
439 yl)propionamide, its isomers, esters, ethers, salts, and  
440 salts of isomers, esters, and ethers;

441 (bb) methyl 2-(1-(4-fluorobenzyl)-1H-indazole-3-  
442 carboxamido)-3-methylbutanoate, its optical, positional, and  
443 geometric isomers, salts, and salts of isomers;

444 (cc) N-(1-phenethylpiperidin-4-yl)-N-  
445 phenylcyclopropanecarboxamide, its isomers, esters, ethers,  
446 salts, and salts of isomers, esters, and ethers;

447 (dd) N-(1-phenethylpiperidin-4-yl)-N-  
448 phenylpentanamide, its isomers, esters, ethers, salts, and  
449 salts of isomers, esters, and ethers;

450 (ee) N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-  
451 yl)butyramide, its isomers, esters, ethers, salts, and salts  
452 of isomers, esters, and ethers;

453 (ff) N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-  
454 yl)butyramide, its isomers, esters, ethers, salts, and salts  
455 of isomers, esters, and ethers;

456 (gg) N-(4-chlorophenyl)-N-(1-phenethylpiperidin-4-  
457 yl)isobutyramide, its isomers, esters, ethers, salts, and  
458 salts of isomers, esters, and ethers;

459 (hh) N-(1-phenethylpiperidin-4-yl)-N-  
460 phenylisobutyramide, its isomers, esters, ethers, salts, and  
461 salts of isomers, esters, and ethers;

462 (ii) N-(1-phenethylpiperidin-4-yl)-N-  
463 phenylcyclopentanecarboxamide, its isomers, esters, ethers,  
464 salts, and salts of isomers, esters, and ethers;

465 (jj) Fentanyl-related substances, their isomers,  
466 esters, ethers, salts, and salts of isomers, esters, and  
467 ethers. Fentanyl-related substance shall mean any substance  
468 not otherwise listed under another Drug Enforcement  
469 Administration Controlled Substance Code Number, and for  
470 which no exemption or approval is in effect under section  
471 505 of the Federal Food, Drug, and Cosmetic Act, 21 U.S.C.  
472 Section 355, that is structurally related to fentanyl by one  
473 or more of the following modifications:

474 a. Replacement of the phenyl portion of the phenethyl  
475 group by any monocycle, whether or not further substituted  
476 in or on the monocycle;

477 b. Substitution in or on the phenethyl group with  
478 alkyl, alkenyl, alkoxy, hydroxyl, halo, haloalkyl, amino or  
479 nitro groups;

480 c. Substitution in or on the piperidine ring with  
481 alkyl, alkenyl, alkoxy, ester, ether, hydroxyl, amino or  
482 nitro groups;

483 d. Replacement of the aniline ring with any aromatic  
484 monocycle, whether or not further substituted in or on the  
485 aromatic monocycle; or

486 e. Replacement of the N-propionyl group by another  
487 acyl group;

488 (kk) Naphthalen-1-yl 1-(5-fluoropentyl)-1H-indole-3-  
489 carboxylate, its optical, positional, and geometric isomers,  
490 salts, and salts of isomers (NM2201; CBL2201);

491 (ll) N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-  
492 fluoropentyl)-1H-indazole-3-carboxamide, its optical,

493 positional, and geometric isomers, salts, and salts of  
494 isomers (5F-AB-PINACA);  
495 (mm) 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-  
496 indazole-3-carboxamide, its optical, positional, and  
497 geometric isomers, salts, and salts of isomers (4-CN-CUMYL-  
498 BUTINACA; 4-cyano-CUMYL-BUTINACA; 4-CN-CUMYLBINACA; CUMYL-  
499 4CN-BINACA; SGT-78);  
500 (nn) methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-  
501 carboxamido)-3-methylbutanoate, its optical, positional, and  
502 geometric isomers, salts, and salts of isomers (MMB-CHMICA,  
503 AMB-CHMICA);  
504 (oo) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-  
505 pyrrolo[2,3-b]pyridine-3-carboxamide, its optical,  
506 positional, and geometric isomers, salts, and salts of  
507 isomers (5F-CUMYL-P7AICA);  
508 (pp) N-ethylpentylone, its optical, positional, and  
509 geometric isomers, salts, and salts of isomers (ephylone, 1-  
510 (1,3-benzodioxol-5-yl)-2-(ethylamino)-pentan-1-one;  
511 (qq) ethyl 2-(1-(5-fluoropentyl)-1H-indazole-3-  
512 carboxamido)-3,3-dimethylbutanoate, its optical, positional,  
513 and geometric isomers, salts, and salts of isomers (trivial  
514 name: 5F-EDMB-PINACA);  
515 (rr) methyl 2-(1-(5-fluoropentyl)-1H-indole-3-  
516 carboxamido)-3,3-dimethylbutanoate, its optical, positional,  
517 and geometric isomers, salts, and salts of isomers (trivial  
518 name: 5F-MDMB-PICA);  
519 (ss) N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-  
520 3-carboxamide, its optical, positional, and geometric  
521 isomers, salts, and salts of isomers (trivial names: FUB-  
522 AKB48; FUB-APINACA; AKB48 N-(4-FLUOROBENZYL));  
523 (tt) 1-(5-fluoropentyl)-N-(2-phenylpropan-2-yl)-1H-  
524 indazole-3-carboxamide, its optical, positional, and

525 geometric isomers, salts, and salts of isomers (trivial  
526 names: 5F-CUMYL-PINACA; SGT-25);  
527 (uu) (1-(4-fluorobenzyl)-1H-indol-3-yl) (2,2,3,3-  
528 tetramethylcyclopropyl) methanone, its optical, positional,  
529 and geometric isomers, salts, and salts of isomers (trivial  
530 name: FUB-144);  
531 (vv) N-ethylhexedrone, its optical, positional, and  
532 geometric isomers, salts, and salts of isomers (Other name:  
533 2-(ethylamino)-1-phenylhexan-1-one);  
534 (ww) alpha-pyrrolidinohexanophenone, its optical,  
535 positional, and geometric isomers, salts, and salts of  
536 isomers (Other names:  $\alpha$ -PHP; alpha-pyrrolidinohexiophenone;  
537 1-phenyl-2-(pyrrolidin-1-yl)hexan-1-one);  
538 (xx) 4-methyl-alpha-ethylaminopentiophenone, its  
539 optical, positional, and geometric isomers, salts, and salts  
540 of isomers; (Other names: 4-MEAP; 2-(ethylamino)-1-(4-  
541 methylphenyl)pentan-1-one);  
542 (yy) 4'-methyl-alpha-pyrrolidinohexiophenone, its  
543 optical, positional, and geometric isomers, salts, and salts  
544 of isomers (Other names: MPHP; 4'-methyl-alpha-  
545 pyrrolidinohexanophenone; 1-(4-methylphenyl)-2-(pyrrolidin-1-  
546 yl)hexan-1-one);  
547 (zz) alpha-pyrrolidinoheptaphenone, its optical,  
548 positional, and geometric isomers, salts, and salts of  
549 isomers (Other names: PV8; 1-phenyl-2-(pyrrolidin-1-  
550 yl)heptan-1-one);  
551 (aaa) 4'-chloro-alpha-pyrrolidinovalerophenone, its  
552 optical, positional, and geometric isomers, salts, and salts  
553 of isomers (Other names: 4-chloro- $\alpha$ -PVP; 4'-chloro-alpha-  
554 pyrrolidinopentiophenone; 1-(4-chlorophenyl)-2-(pyrrolidin-1-  
555 yl)pentan-1-one);

556 (9) Khat, to include all parts of the plant presently  
557 classified botanically as *catha edulis*, whether growing or  
558 not; the seeds thereof; any extract from any part of such  
559 plant; and every compound, manufacture, salt, derivative,  
560 mixture, or preparation of the plant, its seed or extracts;

561 (10) 7-Hydroxymitragynine (methyl (E)-2-  
562 [(2S,3S,7aS,12bS)-3-ethyl-7a-hydroxy-8-methoxy-2,3,4,6,7,12b-  
563 hexahydro-1H-indolo[2,3-a]quinolizin-2-yl]-3-methoxyprop-2-  
564 enoate) concentrated at a level above four hundred parts per  
565 million on a dry-weight basis.

566                   3. The department of health and senior services shall  
567 place a substance in Schedule II if it finds that:

568 (1) The substance has high potential for abuse;

569 (2) The substance has currently accepted medical use  
570 in treatment in the United States, or currently accepted  
571 medical use with severe restrictions; and

572 (3) The abuse of the substance may lead to severe  
573 psychic or physical dependence.

574           4. The controlled substances listed in this subsection  
575 are included in Schedule II:

576 (1) Any of the following substances whether produced  
577 directly or indirectly by extraction from substances of  
578 vegetable origin, or independently by means of chemical  
579 synthesis, or by combination of extraction and chemical  
580 synthesis:

581 (a) Opium and opiate; and any salt, compound,  
582 derivative or preparation of opium or opiate, excluding  
583 apomorphine, thebaine-derived butorphanol, dextrorphan,  
584 nalbuphine, nalmefene, naloxegol, naloxone, and naltrexone,  
585 and their respective salts, but including the following:

586 a. Raw opium;

587 b. Opium extracts;

- 588                   c. Opium fluid;
- 589                   d. Powdered opium;
- 590                   e. Granulated opium;
- 591                   f. Tincture of opium;
- 592                   g. Codeine;
- 593                   h. Dihydroetorphine;
- 594                   i. Ethylmorphine;
- 595                   j. Etorphine hydrochloride;
- 596                   k. Hydrocodone;
- 597                   l. Hydromorphone;
- 598                   m. Metopon;
- 599                   n. Morphine;
- 600                   o. Oripavine;
- 601                   p. Oxycodone;
- 602                   q. Oxymorphone;
- 603                   r. Thebaine;

604                   (b) Any salt, compound, derivative, or preparation  
605                   thereof which is chemically equivalent or identical with any  
606                   of the substances referred to in this subdivision, but not  
607                   including the isoquinoline alkaloids of opium;

- 608                   (c) Opium poppy and poppy straw;
- 609                   (d) Coca leaves and any salt, compound, derivative, or  
610                   preparation of coca leaves, and any salt, compound,  
611                   derivative, or preparation thereof which is chemically  
612                   equivalent or identical with any of these substances, but  
613                   not including the following:

- 614                   a. Decocainized coca leaves or extractions of coca  
615                   leaves, which extractions do not contain cocaine or  
616                   ecgonine; or
- 617                   b. Ioflupane;

618 (e) Concentrate of poppy straw (the crude extract of  
619 poppy straw in either liquid, solid or powder form which  
620 contains the phenanthrene alkaloids of the opium poppy);

621 (2) Any of the following opiates, including their  
622 isomers, esters, ethers, salts, and salts of isomers,  
623 whenever the existence of these isomers, esters, ethers, and  
624 salts is possible within the specific chemical designation,  
625 dextrorphan and levopropoxyphene excepted:

626 (a) Alfentanil;

627 (b) Alphaprodine;

628 (c) Anileridine;

629 (d) Bezetramide;

630 (e) Bulk dextropropoxyphene;

631 (f) Carfentanil;

632 (g) Dihydrocodeine;

633 (h) Diphenoxylate;

634 (i) Fentanyl;

635 (j) Isomethadone;

636 (k) Levo-alphacetylmethadol;

637 (l) Levomethorphan;

638 (m) Levorphanol;

639 (n) Metazocine;

640 (o) Methadone;

641 (p) Methadone-Intermediate, 4-cyano-2-dimethylamino-4,  
642 4-diphenylbutane;

643 (q) Moramide-Intermediate, 2-methyl-3-morpholino-1, 1-  
644 diphenylpropane-carboxylic acid;

645 (r) Pethidine (meperidine);

646 (s) Pethidine-Intermediate-A, 4-cyano-1-methyl-4-  
647 phenylpiperidine;

648 (t) Pethidine-Intermediate-B, ethyl-4-phenylpiperidine-  
649 4-carboxylate;

650 (u) Pethidine-Intermediate-C, 1-methyl-4-  
651 phenylpiperidine-4-carboxylic acid;

652 (v) Phenazocine;

653 (w) Piminodine;

654 (x) Racemethorphan;

655 (y) Racemorphan;

656 (z) Remifentanil;

657 (aa) Sufentanil;

658 (bb) Tapentadol;

659 (cc) Thiafentanil;

660 (3) Any material, compound, mixture, or preparation  
661 which contains any quantity of the following substances  
662 having a stimulant effect on the central nervous system:

663 (a) Amphetamine, its salts, optical isomers, and salts  
664 of its optical isomers;

665 (b) Lisdexamfetamine, its salts, isomers, and salts of  
666 its isomers;

667 (c) Methamphetamine, its salts, isomers, and salts of  
668 its isomers;

669 (d) Phenmetrazine and its salts;

670 (e) Methylphenidate;

671 (4) Any material, compound, mixture, or preparation  
672 which contains any quantity of the following substances  
673 having a depressant effect on the central nervous system,  
674 including its salts, isomers, and salts of isomers whenever  
675 the existence of those salts, isomers, and salts of isomers  
676 is possible within the specific chemical designation:

677 (a) Amobarbital;

678 (b) Glutethimide;

679 (c) Pentobarbital;

680 (d) Phencyclidine;

681 (e) Secobarbital;

682 (5) Hallucinogenic substances:

683 (a) Any material or compound which contains any

684 quantity of nabilone;

685 (b) Dronabinol [(-)- $\Delta$ -9-trans tetrahydrocannabinol] in

686 an oral solution in a drug product approved for marketing by

687 the U.S. Food and Drug Administration;

688 (6) Any material, compound, mixture, or preparation

689 which contains any quantity of the following substances:

690 (a) Immediate precursor to amphetamine and

691 methamphetamine: Phenylacetone;

692 (b) Immediate precursors to phencyclidine (PCP):

693 a. 1-phenylcyclohexylamine;

694 b. 1-piperidinocyclohexanecarbonitrile (PCC);

695 (c) Immediate precursor to fentanyl: 4-anilino-N-

696 phenethyl-4-piperidine (ANPP);

697 (7) Any material, compound, mixture, or preparation

698 which contains any quantity of the following alkyl nitrites:

699 (a) Amyl nitrite;

700 (b) Butyl nitrite.

701 5. The department of health and senior services shall

702 place a substance in Schedule III if it finds that:

703 (1) The substance has a potential for abuse less than

704 the substances listed in Schedules I and II;

705 (2) The substance has currently accepted medical use

706 in treatment in the United States; and

707 (3) Abuse of the substance may lead to moderate or low

708 physical dependence or high psychological dependence.

709 6. The controlled substances listed in this subsection

710 are included in Schedule III:

711 (1) Any material, compound, mixture, or preparation

712 which contains any quantity of the following substances

713 having a potential for abuse associated with a stimulant  
714 effect on the central nervous system:

715 (a) Benzphetamine;  
716 (b) Chlorphentermine;  
717 (c) Clortermine;  
718 (d) Phendimetrazine;

719 (2) Any material, compound, mixture or preparation  
720 which contains any quantity or salt of the following  
721 substances or salts having a depressant effect on the  
722 central nervous system:

723 (a) Any material, compound, mixture or preparation  
724 which contains any quantity or salt of the following  
725 substances combined with one or more active medicinal  
726 ingredients:

727 a. Amobarbital;  
728 b. Secobarbital;  
729 c. Pentobarbital;

730 (b) Any suppository dosage form containing any  
731 quantity or salt of the following:

732 a. Amobarbital;  
733 b. Secobarbital;  
734 c. Pentobarbital;

735 (c) Any substance which contains any quantity of a  
736 derivative of barbituric acid or its salt;

737 (d) Chlorhexadol;  
738 (e) Embutramide;

739 (f) Gamma hydroxybutyric acid and its salts, isomers,  
740 and salts of isomers contained in a drug product for which  
741 an application has been approved under Section 505 of the  
742 federal Food, Drug, and Cosmetic Act;

743 (g) Ketamine, its salts, isomers, and salts of isomers;  
744 (h) Lysergic acid;

745 (i) Lysergic acid amide;

746 (j) Methyprylon;

747 (k) Perampanel, and its salts, isomers, and salts of

748 isomers;

749 (l) Sulfondiethylmethane;

750 (m) Sulfonethylmethane;

751 (n) Sulfonmethane;

752 (o) Tiletamine and zolazepam or any salt thereof;

753 (3) Nalorphine;

754 (4) Any material, compound, mixture, or preparation

755 containing limited quantities of any of the following

756 narcotic drugs or their salts:

757 (a) Not more than 1.8 grams of codeine per one hundred

758 milliliters or not more than ninety milligrams per dosage

759 unit, with an equal or greater quantity of an isoquinoline

760 alkaloid of opium;

761 (b) Not more than 1.8 grams of codeine per one hundred

762 milliliters or not more than ninety milligrams per dosage

763 unit with one or more active, nonnarcotic ingredients in

764 recognized therapeutic amounts;

765 (c) Not more than 1.8 grams of dihydrocodeine per one

766 hundred milliliters or not more than ninety milligrams per

767 dosage unit, with one or more active, nonnarcotic

768 ingredients in recognized therapeutic amounts;

769 (d) Not more than three hundred milligrams of

770 ethylmorphine per one hundred milliliters or not more than

771 fifteen milligrams per dosage unit, with one or more active,

772 nonnarcotic ingredients in recognized therapeutic amounts;

773 (e) Not more than five hundred milligrams of opium per

774 one hundred milliliters or per one hundred grams or not more

775 than twenty-five milligrams per dosage unit, with one or

776 more active nonnarcotic ingredients in recognized  
777 therapeutic amounts;

778 (f) Not more than fifty milligrams of morphine per one  
779 hundred milliliters or per one hundred grams, with one or  
780 more active, nonnarcotic ingredients in recognized  
781 therapeutic amounts;

782 (5) Any material, compound, mixture, or preparation  
783 containing any of the following narcotic drugs or their  
784 salts: Buprenorphine;

785 (6) Anabolic steroids. Any drug or hormonal  
786 substance, chemically and pharmacologically related to  
787 testosterone (other than estrogens, progestins,  
788 corticosteroids, and dehydroepiandrosterone) that promotes  
789 muscle growth, except an anabolic steroid which is expressly  
790 intended for administration through implants to cattle or  
791 other nonhuman species and which has been approved by the  
792 Secretary of Health and Human Services for that  
793 administration. If any person prescribes, dispenses, or  
794 distributes such steroid for human use, such person shall be  
795 considered to have prescribed, dispensed, or distributed an  
796 anabolic steroid within the meaning of this subdivision.  
797 Unless specifically excepted or unless listed in another  
798 schedule, any material, compound, mixture or preparation  
799 containing any quantity of the following substances,  
800 including its salts, esters and ethers:

801 (a) 3 $\beta$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androstane;

802 (b) 3 $\alpha$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androstane;

803 (c) 5 $\alpha$ -androstan-3,17-dione;

804 (d) 1-androstenediol (3 $\beta$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androst-1-  
805 ene);

806 (e) 1-androstenediol (3 $\alpha$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androst-1-  
807 ene);

808 (f) 4-androstenediol ( $3\beta,17\beta$ -dihydroxy-androst-4-ene);  
809 (g) 5-androstenediol ( $3\beta,17\beta$ -dihydroxy-androst-5-ene);  
810 (h) 1-androstenedione ( $[5\alpha]$ -androst-1-en-3,17-dione);  
811 (i) 4-androstenedione (androst-4-en-3,17-dione);  
812 (j) 5-androstenedione (androst-5-en-3,17-dione);  
813 (k) Bolasterone ( $7\alpha, 17\alpha$ -dimethyl- $17\beta$ -hydroxyandrost-4-  
814 en-3-one);  
815 (l) Boldenone ( $17\beta$ -hydroxyandrost-1,4,-diene-3-one);  
816 (m) Boldione;  
817 (n) Calusterone ( $7\beta, 17\alpha$ -dimethyl- $17\beta$ -hydroxyandrost-4-  
818 en-3-one);  
819 (o) Clostebol (4-chloro- $17\beta$ -hydroxyandrost-4-en-3-one);  
820 (p) Dehydrochloromethyltestosterone (4-chloro- $17\beta$ -  
821 hydroxy- $17\alpha$ -methyl-androst-1,4-dien-3-one);  
822 (q) Desoxymethyltestosterone;  
823 (r) 4-dihydrotestosterone ( $17\beta$ -hydroxy-androstan-3-  
824 one);  
825 (s) Drostanolone ( $17\beta$ -hydroxy- $2\alpha$ -methyl- $5\alpha$ -androstan-3-  
826 one);  
827 (t) Ethylestrenol ( $17\alpha$ -ethyl- $17\beta$ -hydroxyestr-4-ene);  
828 (u) Fluoxymesterone (9-fluoro- $17\alpha$ -methyl- $11\beta, 17\beta$ -  
829 dihydroxyandrost-4-en-3-one);  
830 (v) Formebolone (2-formyl- $17\alpha$ -methyl- $11\alpha, 17\beta$ -  
831 dihydroxyandrost-1,4-dien-3-one);  
832 (w) Furazabol ( $17\alpha$ -methyl- $17\beta$ -hydroxyandrostano[2,3-c]-  
833 furazan);  
834 (x)  $13\beta$ -ethyl- $17\beta$ -hydroxygon-4-en-3-one;  
835 (y) 4-hydroxytestosterone ( $4,17\beta$ -dihydroxy-androst-4-  
836 en-3-one);  
837 (z) 4-hydroxy-19-nortestosterone ( $4,17\beta$ -dihydroxy-estr-  
838 4-en-3-one);

839 (aa) Mestanolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxy-5 $\alpha$ -androstan-3-one);  
840  
841 (bb) Mesterolone (1 $\alpha$ -methyl-17 $\beta$ -hydroxy-[5 $\alpha$ ]-  
842 androstan-3-one);  
843 (cc) Methandienone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyandrost-1,4-  
844 dien-3-one);  
845 (dd) Methandriol (17 $\alpha$ -methyl-3 $\beta$ ,17 $\beta$ -dihydroxyandrost-5-  
846 ene);  
847 (ee) Methasterone (2 $\alpha$ ,17 $\alpha$ -dimethyl-5 $\alpha$ -androstan-17 $\beta$ -ol-  
848 3-one);  
849 (ff) Methenolone (1-methyl-17 $\beta$ -hydroxy-5 $\alpha$ -androst-1-en-  
850 3-one);  
851 (gg) 17 $\alpha$ -methyl-3 $\beta$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androstane;  
852 (hh) 17 $\alpha$ -methyl-3 $\alpha$ ,17 $\beta$ -dihydroxy-5 $\alpha$ -androstane;  
853 (ii) 17 $\alpha$ -methyl-3 $\beta$ ,17 $\beta$ -dihydroxyandrost-4-ene;  
854 (jj) 17 $\alpha$ -methyl-4-hydroxynandrolone (17 $\alpha$ -methyl-4-  
855 hydroxy-17 $\beta$ -hydroxyestr-4-en-3-one);  
856 (kk) Methylidienolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyestra-  
857 4,9(10)-dien-3-one);  
858 (ll) Methyltrienolone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyestra-  
859 4,9,11-trien-3-one);  
860 (mm) Methyltestosterone (17 $\alpha$ -methyl-17 $\beta$ -hydroxyandrost-  
861 4-en-3-one);  
862 (nn) Mibolerone (7 $\alpha$ ,17 $\alpha$ -dimethyl-17 $\beta$ -hydroxyestr-4-en-  
863 3-one);  
864 (oo) 17 $\alpha$ -methyl- $\Delta$ 1-dihydrotestosterone (17 $\beta$ -hydroxy-  
865 17 $\alpha$ -methyl-5 $\alpha$ -androst-1-en-3-one) (a.k.a. '17- $\alpha$ -methyl-1-  
866 testosterone');  
867 (pp) Nandrolone (17 $\beta$ -hydroxyestr-4-ene-3-one);  
868 (qq) 19-nor-4-androstenediol (3 $\beta$ ,17 $\beta$ -dihydroxyestr-4-  
869 ene);

870 (rr) 19-nor-4-androstenediol ( $3\alpha,17\beta$ -dihydroxyestr-4-  
871 ene);  
872 (ss) 19-nor-4,9(10)-androstadienedione (estra-4,9(10)-  
873 diene-3,17-dione);  
874 (tt) 19-nor-5-androstenediol ( $3\beta,17\beta$ -dihydroxyestr-5-  
875 ene);  
876 (uu) 19-nor-5-androstenediol ( $3\alpha,17\beta$ -dihydroxyestr-5-  
877 ene);  
878 (vv) 19-nor-4-androstenedione (estr-4-en-3,17-dione);  
879 (ww) 19-nor-5-androstenedione (estr-5-en-3,17-dione);  
880 (xx) Norbolethone ( $13\beta,17\alpha$ -diethyl- $17\beta$ -hydroxygon-4-en-  
881 3-one);  
882 (yy) Norclostebol (4-chloro- $17\beta$ -hydroxyestr-4-en-3-  
883 one);  
884 (zz) Norethandrolone ( $17\alpha$ -ethyl- $17\beta$ -hydroxyestr-4-en-3-  
885 one);  
886 (aaa) Normethandrolone ( $17\alpha$ -methyl- $17\beta$ -hydroxyestr-4-  
887 en-3-one);  
888 (bbb) Oxandrolone ( $17\alpha$ -methyl- $17\beta$ -hydroxy-2-oxa-[5 $\alpha$ ]-  
889 androstan-3-one);  
890 (ccc) Oxymesterone ( $17\alpha$ -methyl-4, $17\beta$ -dihydroxyandrost-  
891 4-en-3-one);  
892 (ddd) metholone ( $17\alpha$ -methyl-2-hydroxymethylene- $17\beta$ -  
893 hydroxy-[5 $\alpha$ ]-androstan-3-one);  
894 (eee) Prostanazol (17 $\beta$ -hydroxy-5 $\alpha$ -androstano[3,2-  
895 c]pyrazole);  
896 (fff) Stanolone ( $\Delta 1$ -dihydrotestosterone (a.k.a. 1-  
897 testosterone) (17 $\beta$ -hydroxy-5 $\alpha$ -androst-1-en-3-one));  
898 (ggg) Stanozolol ( $17\alpha$ -methyl- $17\beta$ -hydroxy-[5 $\alpha$ ]-androst-  
899 2-eno[3,2-c]pyrazole);  
900 (hhh) Stenbolone (17 $\beta$ -hydroxy-2-methyl-[5 $\alpha$ ]-androst-1-  
901 en-3-one);

930           7. The department of health and senior services shall  
931 place a substance in Schedule IV if it finds that:

932 (1) The substance has a low potential for abuse  
933 relative to substances in Schedule III;

934 (2) The substance has currently accepted medical use  
935 in treatment in the United States; and

936 (3) Abuse of the substance may lead to limited  
937 physical dependence or psychological dependence relative to  
938 the substances in Schedule III.

8. The controlled substances listed in this subsection  
are included in Schedule IV:

941 (1) Any material, compound, mixture, or preparation  
942 containing any of the following narcotic drugs or their  
943 salts calculated as the free anhydrous base or alkaloid, in  
944 limited quantities as set forth below:

945 (a) Not more than one milligram of difenoxin and not  
946 less than twenty-five micrograms of atropine sulfate per  
947 dosage unit;

(b) Dextropropoxyphene (alpha-(+)-4-dimethylamino-1, 2-diphenyl-3-methyl-2-propionoxybutane);

950 (c) 2-[(dimethylamino)methyl]-1-(3-  
951 methoxyphenyl)cyclohexanol, its salts, optical and geometric  
952 isomers, and salts of these isomers (including tramadol);

953 (d) Any of the following limited quantities of  
954 narcotic drugs or their salts, which shall include one or  
955 more nonnarcotic active medicinal ingredients in sufficient  
956 proportion to confer upon the compound, mixture or  
957 preparation valuable medicinal qualities other than those  
958 possessed by the narcotic drug alone:

959 a. Not more than two hundred milligrams of codeine per  
960 one hundred milliliters or per one hundred grams;

961                   b. Not more than one hundred milligrams of  
962                   dihydrocodeine per one hundred milliliters or per one  
963                   hundred grams;

964                   c. Not more than one hundred milligrams of  
965        ethylmorphine per one hundred milliliters or per one hundred  
966        grams;

967                   (2) Any material, compound, mixture or preparation  
968        containing any quantity of the following substances,  
969        including their salts, isomers, and salts of isomers  
970        whenever the existence of those salts, isomers, and salts of  
971        isomers is possible within the specific chemical designation:

972                   (a) Alfaxalone;

973                   (b) Alprazolam;

974                   (c) Barbital;

975                   (d) Bromazepam;

976                   (e) Camazepam;

977                   (f) Carisoprodol;

978                   (g) Chloral betaine;

979                   (h) Chloral hydrate;

980                   (i) Chlordiazepoxide;

981                   (j) Clobazam;

982                   (k) Clonazepam;

983                   (l) Clorazepate;

984                   (m) Clotiazepam;

985                   (n) Cloxazolam;

986                   (o) Delorazepam;

987                   (p) Diazepam;

988                   (q) Dichloralphenazone;

989                   (r) Estazolam;

990                   (s) Ethchlorvynol;

991                   (t) Ethinamate;

992                   (u) Ethyl loflazepate;

993                   (v) Fludiazepam;

994                   (w) Flunitrazepam;

995                   (x) Flurazepam;

996 (y) Fospropofol;  
997 (z) Halazepam;  
998 (aa) Haloxazolam;  
999 (bb) Ketazolam;  
1000 (cc) Loprazolam;  
1001 (dd) Lorazepam;  
1002 (ee) Lormetazepam;  
1003 (ff) Mebutamate;  
1004 (gg) Medazepam;  
1005 (hh) Meprobamate;  
1006 (ii) Methohexital;  
1007 (jj) Methylphenobarbital (mephobarbital);  
1008 (kk) Midazolam;  
1009 (ll) Nimetazepam;  
1010 (mm) Nitrazepam;  
1011 (nn) Nordiazepam;  
1012 (oo) Oxazepam;  
1013 (pp) Oxazolam;  
1014 (qq) Paraldehyde;  
1015 (rr) Petrichloral;  
1016 (ss) Phenobarbital;  
1017 (tt) Pinazepam;  
1018 (uu) Prazepam;  
1019 (vv) Quazepam;  
1020 (ww) Suvorexant;  
1021 (xx) Temazepam;  
1022 (yy) Tetrazepam;  
1023 (zz) Triazolam;  
1024 (aaa) Zaleplon;  
1025 (bbb) Zolpidem;  
1026 (ccc) Zopiclone;

1027 (3) Any material, compound, mixture, or preparation  
1028 which contains any quantity of the following substance  
1029 including its salts, isomers and salts of isomers whenever  
1030 the existence of such salts, isomers and salts of isomers is  
1031 possible: fenfluramine;

1032 (4) Any material, compound, mixture, or preparation  
1033 which contains any quantity of the following substances,  
1034 including its salts, isomers, and salts of isomers, whenever  
1035 the existence of such salts, isomers, and salts of isomers  
1036 is possible: Lorcaserin;

1037 (5) Any material, compound, mixture or preparation  
1038 containing any quantity of the following substances having a  
1039 stimulant effect on the central nervous system, including  
1040 their salts, isomers and salts of isomers:

1041 (a) Cathine ((+)-norpseudoephedrine);

1042 (b) Diethylpropion;

1043 (c) Fencamfamin;

1044 (d) Fenproporex;

1045 (e) Mazindol;

1046 (f) Mefenorex;

1047 (g) Modafinil;

1048 (h) Pemoline, including organometallic complexes and  
1049 chelates thereof;

1050 (i) Phentermine;

1051 (j) Pipradrol;

1052 (k) Sibutramine;

1053 (l) SPA ((-)-1-dimethyamino-1,2-diphenylethane);

1054 (6) Any material, compound, mixture or preparation  
1055 containing any quantity of the following substance,  
1056 including its salts:

1057 (a) Butorphanol (including its optical isomers);

1058 (b) Eluxadoline (5-[[[(2S)-2-amino-3-[4-aminocarbonyl)-  
1059 2,6-dimethylphenyl]-1-oxopropyl][(1S)-1-(4-phenyl-1 H-  
1060 imidazol-2-yl)ethyl]amino]methyl]-2-methoxybenzoic acid)  
1061 (including its optical isomers) and its salts, isomers, and  
1062 salts of isomers;

1063 (c) Pentazocine;

1064 (7) Ephedrine, its salts, optical isomers and salts of  
1065 optical isomers, when the substance is the only active  
1066 medicinal ingredient;

1067 (8) The department of health and senior services may  
1068 except by rule any compound, mixture, or preparation  
1069 containing any depressant substance listed in subdivision  
1070 (1) of this subsection from the application of all or any  
1071 part of sections 195.010 to 195.320 and sections 579.015 to  
1072 579.086 if the compound, mixture, or preparation contains  
1073 one or more active medicinal ingredients not having a  
1074 depressant effect on the central nervous system, and if the  
1075 admixtures are included therein in combinations, quantity,  
1076 proportion, or concentration that vitiate the potential for  
1077 abuse of the substances which have a depressant effect on  
1078 the central nervous system.

1079 9. The department of health and senior services shall  
1080 place a substance in Schedule V if it finds that:

1081 (1) The substance has low potential for abuse relative  
1082 to the controlled substances listed in Schedule IV;

1083 (2) The substance has currently accepted medical use  
1084 in treatment in the United States; and

1085 (3) The substance has limited physical dependence or  
1086 psychological dependence liability relative to the  
1087 controlled substances listed in Schedule IV.

1088 10. The controlled substances listed in this  
1089 subsection are included in Schedule V:

1090 (1) Any compound, mixture or preparation containing  
1091 any of the following narcotic drugs or their salts  
1092 calculated as the free anhydrous base or alkaloid, in  
1093 limited quantities as set forth below, which also contains  
1094 one or more nonnarcotic active medicinal ingredients in  
1095 sufficient proportion to confer upon the compound, mixture  
1096 or preparation valuable medicinal qualities other than those  
1097 possessed by the narcotic drug alone:

1098 (a) Not more than two and five-tenths milligrams of  
1099 diphenoxylate and not less than twenty-five micrograms of  
1100 atropine sulfate per dosage unit;

1101 (b) Not more than one hundred milligrams of opium per  
1102 one hundred milliliters or per one hundred grams;

1103 (c) Not more than five-tenths milligram of difenoxin  
1104 and not less than twenty-five micrograms of atropine sulfate  
1105 per dosage unit;

1106 (2) Any material, compound, mixture or preparation  
1107 which contains any quantity of the following substance  
1108 having a stimulant effect on the central nervous system  
1109 including its salts, isomers and salts of isomers:  
1110 pyrovalerone;

1111 (3) Any compound, mixture, or preparation containing  
1112 any detectable quantity of pseudoephedrine or its salts or  
1113 optical isomers, or salts of optical isomers or any  
1114 compound, mixture, or preparation containing any detectable  
1115 quantity of ephedrine or its salts or optical isomers, or  
1116 salts of optical isomers;

1117 (4) Unless specifically exempted or excluded or unless  
1118 listed in another schedule, any material, compound, mixture,  
1119 or preparation which contains any quantity of the following  
1120 substances having a depressant effect on the central nervous  
1121 system, including its salts:

1122 (a) Brivaracetam ((2S)-2-[(4R)-2-oxo-4-  
1123 propylpyrrolidin-1-yl]butanamide) (also referred to as BRV;  
1124 UCB-34714; Briviact);

1125 (b) Ezogabine [N-[2-amino-4(4-fluorobenzylamino)-  
1126 phenyl]-carbamic acid ethyl ester];

1127 (c) Lacosamide [(R)-2-acetoamido-N-benzyl-3-methoxy-  
1128 propionamide];

1129 (d) Pregabalin [(S)-3-(aminomethyl)-5-methylhexanoic  
1130 acid];

1131 (5) Any drug product in finished dosage formulation  
1132 that has been approved by the U.S. Food and Drug  
1133 Administration that contains cannabidiol (2-[1R-3-methyl-6R-  
1134 (1-methylethenyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-  
1135 benzenediol) derived from cannabis and no more than 0.1  
1136 percent (w/w) residual tetrahydro cannabinoids.

1137 11. If any compound, mixture, or preparation as  
1138 specified in subdivision (3) of subsection 10 of this  
1139 section is dispensed, sold, or distributed in a pharmacy  
1140 without a prescription:

1141 (1) All packages of any compound, mixture, or  
1142 preparation containing any detectable quantity of  
1143 pseudoephedrine, its salts or optical isomers, or salts of  
1144 optical isomers or ephedrine, its salts or optical isomers,  
1145 or salts of optical isomers, shall be offered for sale only  
1146 from behind a pharmacy counter where the public is not  
1147 permitted, and only by a registered pharmacist or registered  
1148 pharmacy technician; and

1149 (2) Any person purchasing, receiving or otherwise  
1150 acquiring any compound, mixture, or preparation containing  
1151 any detectable quantity of pseudoephedrine, its salts or  
1152 optical isomers, or salts of optical isomers or ephedrine,

1153 its salts or optical isomers, or salts of optical isomers  
1154 shall be at least eighteen years of age; and

1155 (3) The pharmacist, intern pharmacist, or registered  
1156 pharmacy technician shall require any person, prior to such  
1157 person's purchasing, receiving or otherwise acquiring such  
1158 compound, mixture, or preparation to furnish suitable photo  
1159 identification that is issued by a state or the federal  
1160 government or a document that, with respect to  
1161 identification, is considered acceptable and showing the  
1162 date of birth of the person;

1163 (4) The seller shall deliver the product directly into  
1164 the custody of the purchaser.

1165 12. Pharmacists, intern pharmacists, and registered  
1166 pharmacy technicians shall implement and maintain an  
1167 electronic log of each transaction. Such log shall include  
1168 the following information:

1169 (1) The name, address, and signature of the purchaser;  
1170 (2) The amount of the compound, mixture, or  
1171 preparation purchased;

1172 (3) The date and time of each purchase; and

1173 (4) The name or initials of the pharmacist, intern  
1174 pharmacist, or registered pharmacy technician who dispensed  
1175 the compound, mixture, or preparation to the purchaser.

1176 13. Each pharmacy shall submit information regarding  
1177 sales of any compound, mixture, or preparation as specified  
1178 in subdivision (3) of subsection 10 of this section in  
1179 accordance with transmission methods and frequency  
1180 established by the department by regulation;

1181 14. No person shall dispense, sell, purchase, receive,  
1182 or otherwise acquire quantities greater than those specified  
1183 in this chapter.

1184       15. All persons who dispense or offer for sale  
1185 pseudoephedrine and ephedrine products in a pharmacy shall  
1186 ensure that all such products are located only behind a  
1187 pharmacy counter where the public is not permitted.

1188       16. The penalties for a knowing or reckless violation  
1189 of the provisions of subsections 11 to 15 of this section  
1190 are found in section 579.060.

1191       17. The scheduling of substances specified in  
1192 subdivision (3) of subsection 10 of this section and  
1193 subsections 11, 12, 14, and 15 of this section shall not  
1194 apply to any compounds, mixtures, or preparations that are  
1195 in liquid or liquid-filled gel capsule form or to any  
1196 compound, mixture, or preparation specified in subdivision  
1197 (3) of subsection 10 of this section which must be  
1198 dispensed, sold, or distributed in a pharmacy pursuant to a  
1199 prescription.

1200       18. The manufacturer of a drug product or another  
1201 interested party may apply with the department of health and  
1202 senior services for an exemption from this section. The  
1203 department of health and senior services may grant an  
1204 exemption by rule from this section if the department finds  
1205 the drug product is not used in the illegal manufacture of  
1206 methamphetamine or other controlled or dangerous  
1207 substances. The department of health and senior services  
1208 shall rely on reports from law enforcement and law  
1209 enforcement evidentiary laboratories in determining if the  
1210 proposed product can be used to manufacture illicit  
1211 controlled substances.

1212       19. The department of health and senior services shall  
1213 revise and republish the schedules annually.

1214       20. The department of health and senior services shall  
1215 promulgate rules under chapter 536 regarding the security

1216 and storage of Schedule V controlled substances, as  
1217 described in subdivision (3) of subsection 10 of this  
1218 section, for distributors as registered by the department of  
1219 health and senior services.

1220 21. Logs of transactions required to be kept and  
1221 maintained by this section and section 195.417 shall create  
1222 a rebuttable presumption that the person whose name appears  
1223 in the logs is the person whose transactions are recorded in  
1224 the logs.

✓